Ignite Creation Date:
2025-12-25 @ 12:09 AM
Ignite Modification Date:
2026-01-04 @ 1:48 AM
Study NCT ID:
NCT01676558
Status:
UNKNOWN
Last Update Posted:
2012-11-14
First Post:
2012-08-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor:
Korea Cancer Center Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
DLBCL_131I-rituximab RIT
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None